The Role of SNORD116-24: A Promising Disease Drug Target and Biomarker

Target Name: SNORD116-24

NCBI ID: G100033435

SNORD116-24

Other Name(s): HBII-85-24 | Small nucleolar RNA, C/D box 116-24 | small nucleolar RNA, C/D box 116-24

The Role of SNORD116-24: A Promising Disease Drug Target and Biomarker

Introduction
SNORD116-24 is an important molecule that has attracted significant attention in the field of medical research due to its potential role as a disease drug target or biomarker. This small nucleolar RNA molecule is involved in various cellular processes, and its dysregulation has been implicated in several diseases. In this article, we will explore the significance of SNORD116-24, its functions, and its potential as a therapeutic target or biomarker for various conditions.

The Functions of SNORD116-24
SNORD116-24 belongs to a class of molecules known as small nucleolar RNAs (snoRNAs). SnoRNAs, including SNORD116-24, are best known for their involvement in the modification and processing of other RNA molecules, such as ribosomal RNAs and small nuclear RNAs. These modifications play crucial roles in the regulation of gene expression and overall cellular function.

Specifically, SNORD116-24 is involved in the methylation of ribosomal RNAs, which is important for the proper functioning of ribosomes in protein synthesis. Additionally, SNORD116-24 has been found to influence the expression of genes involved in neurological development and function. Interestingly, this snoRNA is primarily expressed in the brain and has been implicated in neurodevelopmental disorders.

SNORD116-24 as a Disease Drug Target
The dysregulation of SNORD116-24 has been observed in several diseases, making it an attractive target for therapeutic interventions. One notable condition where SNORD116-24 has shown potential as a drug target is Prader-Willi syndrome (PWS), a rare genetic disorder characterized by developmental delays, intellectual disabilities, and an insatiable appetite leading to obesity.

Studies have found that SNORD116-24 is located within a region of chromosome 15 that is typically deleted in individuals with PWS. This genetic deletion leads to the loss of SNORD116-24 expression, which is believed to contribute to the development of the syndrome. Restoring or enhancing the expression of SNORD116-24 could potentially alleviate some of the symptoms associated with PWS. Therefore, the development of therapeutic strategies targeting SNORD116-24 holds promise as a potential treatment for this debilitating condition.

Furthermore, SNORD116-24 aberrations have also been associated with other neurological disorders, such as autism spectrum disorders and schizophrenia. These findings suggest that targeting SNORD116-24 could potentially offer new avenues for drug development in the field of neuroscience.

SNORD116-24 as a Biomarker
In addition to its potential as a therapeutic target, SNORD116-24 has also shown promise as a biomarker for certain diseases. A biomarker is a measurable indicator of biological processes or conditions that can be used to diagnose, monitor, or predict the progression of a disease.

In the case of PWS, the absence or reduced expression of SNORD116-24 can serve as a diagnostic biomarker for identifying individuals with the syndrome. This molecular marker offers a non-invasive and reliable method to confirm the presence of the disease, allowing for early intervention and personalized treatment strategies.

Moreover, SNORD116-24 expression levels have been shown to vary in different cancer types. For example, downregulation of SNORD116-24 has been observed in lung cancer, colorectal cancer, and breast cancer. Detecting these alterations in SNORD116-24 expression could potentially aid in cancer diagnosis, prognosis, and therapeutic decision-making.

Conclusion
SNORD116-24 represents a molecular target of considerable interest in the field of medical research. Its diverse roles in cellular processes, particularly within the brain, make it an attractive candidate for therapeutic interventions and as a diagnostic biomarker. Further investigations into the functions and mechanisms of SNORD116-24 may pave the way for the development of innovative therapies and diagnostic tools for various diseases, improving patient outcomes and quality of life.

Protein Name: Small Nucleolar RNA, C/D Box 116-24

The "SNORD116-24 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD116-24 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets